Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J. Thromb. Haemost., 18, 844, 10.1111/jth.14768

Harzallah, 2020, Lupus anticoagulant is frequent in patients with Covid-19, J. Thromb. Haemost.

Connell, 2020, Coagulopathy of COVID-19 and antiphospholipid antibodies, J. Thromb. Haemost., 10.1111/jth.14893

Helms, 2020, High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med., 10.1007/s00134-020-06062-x

Zhang, 2020, Coagulopathy and antiphospholipid antibodies in patients with Covid-19, N. Engl. J. Med., 382, 10.1056/NEJMc2007575

De Kesel, 2019, The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: can activated carbon eliminate false-positive results?, Res. Pract. Thromb. Haemost., 4, 161, 10.1002/rth2.12264

Tripodi, 2019, J. Thromb. Haemost., 17, 1715, 10.1111/jth.14560

Schouwers, 2010, Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?, Thromb. Res., 125, 102, 10.1016/j.thromres.2009.09.001

Abdel-Wahab, 2018, Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis, Lupus, 27, 572, 10.1177/0961203317731532

Olsen, 2013, Multifaceted effects of hydroxychloroquine in human disease, Semin. Arthritis Rheum., 43, 264, 10.1016/j.semarthrit.2013.01.001